Literature DB >> 11838615

Helicobacter pylori: diseases, tests and treatment.

U Vaira1, L Gatta, C Ricci, L D'Anna, M M Iglioli.   

Abstract

Gastroduodenal disease associated with Helicobacter pylori infection are reviewed as well as the diagnostic approach. Generally, there are by and large two ways in which a diagnosis of infection by Helicobacter pylori can be made: by using either an invasive or non-invasive procedure. The invasive procedures involve endoscopy and biopsy Biopsy is essential since the mucosa may often appear macroscopically normal but, nevertheless, be inflamed. Once a biopsy is obtained histological examination, culture, polymerase chain reaction, detection of the presence of urease activity can be detected. The non-invasive tests that can be used to diagnose the infection are: serology, detection of labelled metabolic products of urea hydrolysis either in the breath (13CO2, 14CO2), the urine or the blood, detection of Helicobacter pylori antigen in stool specimen. At present, no single test is sufficiently reliable to definitely detect colonisation by Helicobacter pylori, and a combination of two is recommended, if feasible. Choice of the test to be used is not straightforward and relies on a series of situations, i. e., clinical setting and local expertise and availability, that the clinician must consider to obtain the best diagnostic yeld. The challenge of Helicobacter pylori eradication is not very easy to obtain. The possible scenario and the use of a new proton pump inhibitor (esomeprazole) are reviewed and discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11838615     DOI: 10.1016/s1590-8658(01)80697-6

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  8 in total

1.  Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.

Authors:  Xiao-Zhong Gao; Xiu-Li Qiao; Wen-Chong Song; Xiao-Feng Wang; Feng Liu
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

2.  Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial.

Authors:  Mohamed H Emara; Salem Y Mohamed; Hesham R Abdel-Aziz
Journal:  Therap Adv Gastroenterol       Date:  2014-01       Impact factor: 4.409

3.  Helicobacter pylori and recurrent pain abdomen.

Authors:  Niranjan Biswal; N Ananathakrishnan; Vikram Kate; S Srinivasan; P Nalini; Betsy Mathai
Journal:  Indian J Pediatr       Date:  2005-07       Impact factor: 1.967

Review 4.  Bleeding peptic ulcer in the elderly: risk factors and prevention strategies.

Authors:  Angelo Zullo; Cesare Hassan; Salvatore M A Campo; Sergio Morini
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

5.  Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.

Authors:  Giuseppe Scaccianoce; Cesare Hassan; Alba Panarese; Donato Piglionica; Sergio Morini; Angelo Zullo
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

Review 6.  The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis.

Authors:  Angelo Zullo; Vincenzo De Francesco; Cesare Hassan; Sergio Morini; Dino Vaira
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

7.  Modified Sequential Therapy Regimen versus Conventional Triple Therapy for Helicobacter Pylori Eradication in Duodenal Ulcer Patients in China: A Multicenter Clinical Comparative Study.

Authors:  Ying-Qun Zhou; Ling Xu; Bing-Fang Wang; Xiao-Ming Fan; Jian-Ye Wu; Chun-Yan Wang; Chuan-Yong Guo; Xuan-Fu Xu
Journal:  Gastroenterol Res Pract       Date:  2011-11-21       Impact factor: 2.260

8.  Association of Helicobacter pylori infection with the risk of metabolic syndrome and insulin resistance: an updated systematic review and meta-analysis.

Authors:  Mobin Azami; Hamid Reza Baradaran; Hojat Dehghanbanadaki; Parisa Kohnepoushi; Lotfolah Saed; Asra Moradkhani; Farhad Moradpour; Yousef Moradi
Journal:  Diabetol Metab Syndr       Date:  2021-12-18       Impact factor: 3.320

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.